Codexis discovers, develops and sells enzymes and other proteins to its clients. Co.'s business segments are: Performance Enzymes, which uses its technology to develop enzymes for customers using next generation sequencing and polymerase chain reaction for in vitro molecular diagnostic and molecular biology research applications, as well DNA/RNA synthesis and health monitoring applications; and Novel Biotherapeutics, which discovers, improves, and/or develops biotherapeutic drug candidates, including CDX-6114 for the potential treatment of hyperphenylalaninemia. Co.'s products include biocatalysts, chemical intermediates and Codex® biocatalyst panels and kits. The CDXS stock yearly return is shown above.
The yearly return on the CDXS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CDXS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|